Allogene Therapeutics (ALLO) EBT Margin (2021 - 2024)
Allogene Therapeutics (ALLO) reported EBT Margin of 353104.55% for Q1 2024, down 1966121.0% on a YoY basis from N/an in Q2 2023, and down 1.8% sequentially from 346876.19% in Q4 2023.
Allogene Therapeutics (ALLO) EBT Margin (2021 - 2024) Analysis & Trends
Allogene Therapeutics (ALLO) has 4 years of EBT Margin data on file, last reported at 353104.55% in Q1 2024.
- For the quarter ending Q1 2024, EBT Margin fell 1966121.0% year-over-year to 353104.55%; the trailing twelve-month figure through Dec 2024 stood at 1844954.55% (down 144767665.0% YoY), and the FY2024 full-year result was 1168850.0%, down 82436053.0% from the prior year.
- EBT Margin slipped to 353104.55% in Q1 2024, from 346876.19% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 0.01% in Q4 2021 to a low of 833066.67% in Q3 2022.
- A 4-year average of 324906.39% and a median of 333947.73% in 2021 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin slumped 50573401 bps in 2022 and soared 41701212 bps in 2023, its largest moves.
- Tracing ALLO's EBT Margin over 4 years: stood at 0.01% in 2021, then slumped by 2000000000 bps to 386684.62% in 2022, then gained by 10 bps to 346876.19% in 2023, then fell by 2 bps to 353104.55% in 2024.
- Business Quant data shows ALLO's EBT Margin at 353104.55% in Q1 2024, 346876.19% in Q4 2023, and 416054.55% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -353,104.55% |
| Dec 31, 2023 | -346,876.19% |
| Sep 30, 2023 | -416,054.55% |
| Jun 30, 2023 | -513,659.09% |
| Mar 31, 2023 | -333,443.33% |
| Dec 31, 2022 | -386,684.62% |
| Sep 30, 2022 | -833,066.67% |
| Jun 30, 2022 | -170,493.75% |
| Mar 31, 2022 | -209,030.77% |
| Dec 31, 2021 | -0.01% |
| Sep 30, 2021 | -327,332.65% |
| Jun 30, 2021 | -333,947.73% |
| Mar 31, 2021 | -89.19% |